Latest Medical Imaging News
Imricor Submits Third of Four FDA Modules Ahead of 2026 US Approval Target
Micro-X Secures $1.6M ARPA-H Payment as Full Body CT Clears Design Review
Resonance Health Targets Liver Fibrosis Device for $40B Diagnostics Market
333D Takes $150K Stake in NVIDIA-Backed $5.5B AI Data Centre Ahead of 2026 Listing
4DMedical Eyes $2.5B PE Market as CLEAR Program Targets 5M Annual US Scans
Optiscan Hits Study Halfway Mark With FDA Submission on Track for Late 2026
Pro Medicus Locks in A$16M Renewal as Ohio State Expands Its Imaging Platform
Medical Imaging Analysis
Pro Medicus Fell 62%: Why the Share Price Is Still Not Cheap
ASX Healthcare’s 16-Point Gap: Structural Case, Missing Catalyst
Pro Medicus Down 41%: Great Business, but Is It Cheap?
Pro Medicus Share Price: Cheaper, but Still Priced for Perfection
Telix Hits US$1B in Revenue. Why the Stock Is Down 38%
Discover More in the Medical Diagnostics Hub
Go to HubFeatured ASX Medical Imaging Announcements
4DMedical Eyes $2.5B PE Market as CLEAR Program Targets 5M Annual US Scans
Video
4DMedical Eyes $2.5B Pulmonary Market With Contrast-Free Imaging Tech
Video
4DMedical Acquires contextflow for European Expansion at 6.5% of Cash Balance
Video
4DMedical Secures Commercial SimonMed Contract Across 170 US Imaging Centres
Video
4DMedical Study Shows Its CT:VQ Tech Nearly Doubles Lung Surgery Success Rates
Video
Enlitic Lands First New Zealand Customer as It Goes Live at 65-Clinic Network
Latest ASX Medical Imaging Videos
Medical Imaging Stocks: Technology Advances, Market Trends and Investor Analysis
The medical imaging sector encompasses hardware manufacturers, software platform developers, radiopharmaceutical companies, and AI-driven radiology tools, creating a diverse investment landscape with distinct growth and risk profiles. Traditional imaging hardware is a mature market dominated by global leaders, while AI radiology and molecular imaging represent high-growth segments attracting significant venture and public market capital. ASX-listed companies are active in nuclear medicine, radiopharmaceuticals, and imaging software, with several achieving international commercial scale. Regulatory approval pathways for imaging AI are evolving, creating both opportunity and uncertainty for investors. StockWire X tracks medical imaging company results, technology announcements, FDA and TGA clearances, and M&A developments to give investors comprehensive sector coverage.
Frequently Asked Questions
What are the best medical imaging stocks to invest in?
The strongest medical imaging investment candidates combine proprietary imaging technology, regulatory approvals in major markets, and a clear path to recurring revenue through consumables, software subscriptions, or service contracts. AI-powered radiology companies are attracting significant investor interest. StockWire X covers medical imaging stocks across ASX and global markets.
What is the medical imaging market size and growth outlook?
The global medical imaging market is one of the larger segments of the medtech industry, driven by ageing populations, rising chronic disease prevalence, and ongoing technology innovation in AI radiology, molecular imaging, and point-of-care diagnostics. Investors tracking medical imaging companies should monitor market share dynamics and technology adoption rates alongside company fundamentals.
How is AI changing medical imaging investment opportunities?
AI is transforming medical imaging by enabling automated image analysis, faster diagnostic reporting, and improved accuracy. AI radiology platforms have attracted significant venture and public market capital, with several products achieving FDA clearance for clinical use. For investors, AI in medical imaging represents a high-growth software layer being applied to a large, established hardware market.
How is artificial intelligence transforming the medical imaging industry?
AI applications in medical imaging include automated image analysis for radiology, pathology, and ophthalmology, where algorithms detect abnormalities, quantify disease severity, and prioritise urgent cases for review. Listed companies are commercialising AI imaging software as standalone diagnostic tools and integrated modules within imaging systems. The FDA has cleared hundreds of AI-enabled medical devices. Investors assess the evidence base supporting clinical utility, reimbursement status, and defensibility of AI model performance.
What is the medical imaging equipment replacement cycle and how does it affect sector demand?
Medical imaging equipment including MRI, CT, and ultrasound systems has typical operational lifespans of ten to fifteen years. The replacement cycle creates relatively predictable baseline demand for equipment manufacturers. Accelerating factors include technology upgrades offering improved diagnostic capability and new clinical applications requiring next-generation systems. Countries with ageing equipment inventories represent concentrated demand opportunities for leading manufacturers.